drugset / Trial / NCT05106023

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

NCT05106023

Phase 2 Unknown 31 enrolled Yong Chen
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to explore the efficacy and safety of SHR-1701 combined with temozolomide in the treatment of advanced melanoma.

Timeline

Start
2022-01-21
Primary completion
2023-09-30
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Retlirafusp alfa Protein / enzyme biologic
Subject Temozolomide Small molecule

Indications